Please ensure Javascript is enabled for purposes of website accessibility
United Therapeutics Stock Quote

United Therapeutics (NASDAQ: UTHR)

$207.62
(-0.2%)
-$0.36
Price as of September 23, 2022, 4:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

United Therapeutics Returns vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
UTHR +3.57% +81.17% +12.61% +3,307%
S&P -16.99% +47.60% +8.09% +176%

United Therapeutics Company Info

A biotechnology company focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.

News & Analysis

The Fool has written over 100 articles on United Therapeutics.
How United Therapeutics Trounced Wall Street's Q3 Estimates
Keith Speights  |  Oct 30, 2019

Revenue and earnings fell from the prior-year period, but the drugmaker blew past analysts' estimates thanks to a combination of factors.

Here's Why United Therapeutics Fell 18.1% in May
Maxx Chatsko  |  Jun 6, 2019

The stock has now fallen nearly 30% since the end of March.

Here's Why Arena Pharmaceuticals Jumped as Much as 30.6% Today
Maxx Chatsko  |  Nov 15, 2018

The company moved to immediately monetize a promising drug candidate. For a cool $800 million up-front payment, investors can't complain.

Is MannKind Corporation Stock a Buy?
Motley Fool Staff  |  Sep 8, 2018

A new collaboration is funneling tens of millions of dollars onto the diabetes company’s balance sheet.

The Probable Reason Why MannKind Corporation Is Rallying Again
Brian Feroldi  |  Sep 5, 2018

Shares soar for the second day in a row. What can explain the bullish move?

Why MannKind Corporation Stock Is Skyrocketing Today
Brian Feroldi  |  Sep 4, 2018

Shares are soaring following the company's announcement of a new partnership agreement. Here's what investors need to know.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.